膀胱尿路上皮癌根治性膀胱切除术患者的管理趋势与结局:南加州大学3347例经验演变
该研究分析1971至2018年在一家学术中心接受根治性膀胱切除术的3347例膀胱尿路上皮癌患者的纵向队列,评估管理方式演变对结局的影响。结果显示近十年70.9%病例仍为开放手术,机器人辅助手术自2009年上升,新辅助化疗使用增加且pT0N0M0率改善(p=0.013),但无复发生存趋势无变化(p=0.73),总生存改善(1990-1999年5年概率51% vs 2010-2018年62%,p=0.019)。
要点
- 近十年70.9%病例行开放根治性膀胱切除术,机器人辅助手术自2009年上升。
- 新辅助化疗使用随时间增加,辅助化疗减少,pT0N0M0率改善(p=0.013)。
- 无复发生存趋势稳定(p=0.73),总生存改善(1990-1999年51% vs 2010-2018年62%,p=0.019)。
核心结论
- 尽管围手术期和手术技术进步且pT0N0M0率改善,根治性膀胱切除术后无复发生存趋势无总体变化,但总生存率改善。
- 新辅助化疗降期的患者获益大,但真实世界经验强调需预先识别可能术后结局更差的新辅助化疗无应答者。
研究设计与样本
- 纵向队列研究,纳入1971年至2018年在一家学术中心接受根治性膀胱切除术的3347例患者。
- 采用单变量和多变量模型评估关联。
主要发现
- 近十年70.9%病例行开放根治性膀胱切除术,机器人辅助根治性膀胱切除术趋势自2009年上升。
- 淋巴结清扫模板保持一致,但2002年淋巴结送检改为解剖包,检出率增加(p<0.001)。
- 新辅助化疗使用随时间增加,辅助化疗相应减少,近十年显著(p<0.001),且与pT0N0M0率改善一致(p=0.013)。
- 中位5年无复发生存和总生存概率分别为65%和55%。
- 晚期分期、新辅助化疗、根治性膀胱切除术延迟、淋巴血管侵犯和切缘阳性与更差无复发生存相关(多变量p<0.001)。
关键数值与推荐
- 无复发生存随时间保持稳定(p=0.73)。
- 总生存改善:5年概率1990-1999年51% vs 2010-2018年62%(p=0.019)。
- 在膀胱外和/或淋巴结阳性疾病患者中,接受新辅助化疗者结局比直接行根治性膀胱切除术者更差(p≤0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are conflicting reports on outcome trends following radical cystectomy (RC) for bladder cancer. MATERIALS AND METHODS: Evolution of modern bladder cancer management and its impact on outcomes was analyzed using a longitudinal cohort of 3,347 patients who underwent RC at an academic center between 1971 and 2018. Outcomes included recurrence-free survival (RFS) and overall survival (OS). Associations were assessed using univariable and multivariable models. RESULTS: In all, 70.9% of cases underwent open RC in the last decade, although trend for robot-assisted RC rose since 2009. While lymphadenectomy template remained consistent, nodal submission changed to anatomical packets in 2002 with increase in yield (p <0.001). Neoadjuvant chemotherapy (NAC) use increased with time with concomitant decrease in adjuvant chemotherapy; this was notable in the last decade (p <0.001) and coincided with improved pT0N0M0 rate (p=0.013). Median 5-year RFS and OS probabilities were 65% and 55%, respectively. Advanced stage, NAC, delay to RC, lymphovascular invasion and positive margins were associated with worse RFS (all, multivariable p <0.001). RFS remained stable over time (p=0.73) but OS improved (5-year probability, 1990-1999 51%, 2010-2018 62%; p=0.019). Among patients with extravesical and/or node-positive disease, those who received NAC had worse outcomes than those who directly underwent RC (p ≤0.001). CONCLUSIONS: Despite perioperative and surgical advances, and improved pT0N0M0 rates, there has been no overall change in RFS trend following RC, although OS rates have improved. While patients who are downstaged with NAC derive great benefit, our real-world experience highlights the importance of preemptively identifying NAC nonresponders who may have worse post-RC outcomes.
引用
- Mitra AP, Cai J, Miranda G, et al. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. J Urol. 2021. PMID: 34994657. doi:10.1097/JU.0000000000002242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。